Shots:

• For smaller volume agreements- the company has priced its COVID-19 vaccine ranging from $32-$37/ dose- higher than the price of Pfizer’s vaccine candidate
• The company is in talks with several countries for supply agreements of its vaccine- adding that it had already received about $400M for supply. The P-III study of mRNA-1273 is being conducted in collaboration with NIH and BARDA with an anticipated completion of enrollment in Sept’2020
• Moderna has received $1B from the US government under a plan to ramp up vaccine development. The company’s vaccine candidate is one of the few that have already advanced to the final stage of testing

­ Ref: Reuters | Image: Moderna